Shift Bioscience CEO and founder Daniel Ives (L) at the startup's headquarters in Cambridge, UK
October 14, 2024 07:00 AM EDT
Financing
Startups
R&D

Ex­clu­sive: British start­up rais­es $16M to find genes that rewind the epi­ge­net­ic clock

Ryan Cross

Senior Science Correspondent

Sev­en years ago, Daniel Ives be­lieved that he was on the cusp of solv­ing ag­ing. He want­ed to con­tin­ue work­ing on a dis­cov­ery he made …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

Catal­ent sells New Jer­sey plant to Bel­gian CD­MO, plans mov­ing HQ else­where

FDA to re­con­sid­er re­moval of Lil­ly's GLP-1 drug from short­age list, a win for com­pound­ing phar­ma­cies

Trans­gene shares dip as ther­a­peu­tic can­cer vac­cine dis­ap­points in Phase 2 tri­al

Pfiz­er gets an FDA win in he­mo­phil­ia af­ter a rough week

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times